IDH1 and acute myeloid leukemia: In addition, increased sensitivity of IDH1-mut versus IDH1-wt cells to 5-azacytidine could be confirmed, which supports data from recent clinical trials suggesting 5-azacytidine as combinational partner for ivosidenib treatment of patients with IDH1-mut AML [43].